Drug Trial Radar · NCT07059767
Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jun 24, 2025
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Ethris GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- VirTus Respiratory Research Ltd
- First posted
- Jul 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge
Conditions
- Asthma (Diagnosis)
Interventions
ETH47Drug
single intranasal dose of ETH47
PlaceboDrug
single intranasal dose of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in peak of total lower respiratory symptoms score (LRSS)Time frame: Day 1 to Day 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Imperial College Healthcare NHS Trust
London, United Kingdom
Medicines Evaluation Unit Limited
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.